Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Drugs in R&D|November 27, 2023
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated MetabolismNicola Ferri, Sara De Martin, James Stuart, et al.
Drugs in R&D|August 2, 2024
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic ImpairmentNicola Ferri, Sara De Martin, James Stuart, et al.
Frontiers in Psychiatry|July 17, 2023
Urgent psychiatric consultations for suicide attempt and suicidal ideation before and after the COVID-19 pandemic in an Italian pediatric emergency settingMassimo Apicella, Giulia Serra, Monia Trasolini, et al.
Journal of Personalized Medicine|February 25, 2023
Eye Movement Desensitization and Reprocessing (EMDR) as a Possible Evidence-Based Rehabilitation Treatment Option for a Patient with ADHD and History of Adverse Childhood Experiences: A Case Report StudyClotilde Guidetti, Patrizia Brogna, Daniela Pia Rosaria Chieffo, et al.
The Journal of Clinical Psychiatry|October 8, 2025
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled TrialClotilde Guidetti, George I Papakostas, Luca Pani, et al.
International Journal of Molecular Sciences|October 27, 2022
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated SignalingStephen M Stahl, Sara De Martin, Andrea Mattarei, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressantMaurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology|February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressantsClotilde Guidetti, George I Papakostas, Steven Stahl, et al.
The Journal of Clinical Psychiatry|February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label StudyMaurizio Fava, Luca Pani, Sara De Martin, et al.
The American Journal of Psychiatry|December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind TrialMaurizio Fava, Stephen Stahl, Luca Pani, et al.
Pageof 3